Stentys to Present First Results of Sirolimus-Eluting Self-Apposing® Stent at TCT Conference
STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced that the 4-month results of the APPOSITION IV trial will be disclosed during the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
Help employers find you! Check out all the jobs and post your resume.